Abstract
Evidence regarding the synergistic association between EGFR-TKIs and metformin has been controversial, with conflicting results from phase II clinical trials performed in different populations. The reasons for the discrepancies could be related to differences in the populations studied in each single-country trial. Interestingly, one factor which was not evaluated in either trial was whether the benefit from metformin was dependent on body mass index (BMI) or baseline glucose uptake by the tumor through PET-CT-FDG.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call